长春新区政府投资基金支持企业创新药获国际临床突破

Group 1 - Excyte Biopharma Ltd. has officially launched a Phase I clinical trial for its core product YK012, a bispecific antibody targeting CD3/CD19, for primary membranous nephropathy (pMN) in the United States [1] - The trial was registered on ClinicalTrials.gov on November 18, 2025, marking a significant step in Excyte's international research and development in the field of autoimmune diseases [1] - Excyte Biopharma, established in 2016, focuses on the development of bispecific antibody drugs and has a complete development platform with unique technical advantages in drug structure design, affinity optimization, and safety regulation [1] Group 2 - The Changchun New Area Government Investment Fund made a forward-looking investment in Excyte Biopharma in June 2024, providing critical resources for the early-stage development of YK012 and accelerating its clinical progress [2] - This investment reflects the fund's strategic support and precise layout in the field of biopharmaceutical innovation, which will also promote local talent cultivation, technological innovation, and industrial chain aggregation [2] - The ongoing wave of domestic innovative drugs entering international markets will see the Changchun New Area Government Investment Fund continue to support innovative enterprises, effectively promoting regional industrial structure optimization and upgrading [2]